Cargando…
How I treat anaplastic glioma without 1p/19q codeletion
Anaplastic astrocytoma without 1p/19q codeletion is a rare primary central nervous system tumour occurring primarily in middle-aged adults and associated with a median survival of 5–10 years. The major corner stone of treatment is maximal safe neurosurgical resection, followed by radiotherapy and ch...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735673/ https://www.ncbi.nlm.nih.gov/pubmed/31555489 http://dx.doi.org/10.1136/esmoopen-2019-000534 |
_version_ | 1783450392516886528 |
---|---|
author | Berghoff, Anna van den Bent, Martin |
author_facet | Berghoff, Anna van den Bent, Martin |
author_sort | Berghoff, Anna |
collection | PubMed |
description | Anaplastic astrocytoma without 1p/19q codeletion is a rare primary central nervous system tumour occurring primarily in middle-aged adults and associated with a median survival of 5–10 years. The major corner stone of treatment is maximal safe neurosurgical resection, followed by radiotherapy and chemotherapy. Several clinical trials addressed the optimal adjuvant treatment; however, interpretation has been challenged by the recent molecular marker-based reclassification of tumour. The interim study of the CATNON trial strongly suggests the addition of 12 adjuvant cycles of temozolomide in addition to radiotherapy after maximal safe resection in patients with anaplastic astrocytoma without 1p/19q codeletion. Based on more recently presented data from the second interim analysis of the CATNON trial and from the molecular analysis, benefit from temozolomide during and after radiotherapy is limited to patients with isocitrate dehydrogenase-mutated anaplastic astrocytoma. Given the small patient number in the single subgroups and the so far missing neurocognitive and quality of life data, more mature analyses needs to be awaited to draw final conclusions on the application of concurrent temozolomide treatment for the daily routine in patients who already are scheduled for adjuvant temozolomide. Further molecular analysis is ongoing to define personalised treatment approaches in patients with anaplastic astrocytoma. |
format | Online Article Text |
id | pubmed-6735673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-67356732019-09-25 How I treat anaplastic glioma without 1p/19q codeletion Berghoff, Anna van den Bent, Martin ESMO Open Review Anaplastic astrocytoma without 1p/19q codeletion is a rare primary central nervous system tumour occurring primarily in middle-aged adults and associated with a median survival of 5–10 years. The major corner stone of treatment is maximal safe neurosurgical resection, followed by radiotherapy and chemotherapy. Several clinical trials addressed the optimal adjuvant treatment; however, interpretation has been challenged by the recent molecular marker-based reclassification of tumour. The interim study of the CATNON trial strongly suggests the addition of 12 adjuvant cycles of temozolomide in addition to radiotherapy after maximal safe resection in patients with anaplastic astrocytoma without 1p/19q codeletion. Based on more recently presented data from the second interim analysis of the CATNON trial and from the molecular analysis, benefit from temozolomide during and after radiotherapy is limited to patients with isocitrate dehydrogenase-mutated anaplastic astrocytoma. Given the small patient number in the single subgroups and the so far missing neurocognitive and quality of life data, more mature analyses needs to be awaited to draw final conclusions on the application of concurrent temozolomide treatment for the daily routine in patients who already are scheduled for adjuvant temozolomide. Further molecular analysis is ongoing to define personalised treatment approaches in patients with anaplastic astrocytoma. BMJ Publishing Group 2019-08-20 /pmc/articles/PMC6735673/ /pubmed/31555489 http://dx.doi.org/10.1136/esmoopen-2019-000534 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Berghoff, Anna van den Bent, Martin How I treat anaplastic glioma without 1p/19q codeletion |
title | How I treat anaplastic glioma without 1p/19q codeletion |
title_full | How I treat anaplastic glioma without 1p/19q codeletion |
title_fullStr | How I treat anaplastic glioma without 1p/19q codeletion |
title_full_unstemmed | How I treat anaplastic glioma without 1p/19q codeletion |
title_short | How I treat anaplastic glioma without 1p/19q codeletion |
title_sort | how i treat anaplastic glioma without 1p/19q codeletion |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735673/ https://www.ncbi.nlm.nih.gov/pubmed/31555489 http://dx.doi.org/10.1136/esmoopen-2019-000534 |
work_keys_str_mv | AT berghoffanna howitreatanaplasticgliomawithout1p19qcodeletion AT vandenbentmartin howitreatanaplasticgliomawithout1p19qcodeletion |